Intracranial activity of ceritinib in crizotinib-pretreated and crizotinib-naïve ALK-positive NSCLC patients

In 3 % to 5 % of cases, lung cancer is associated with ALK rearrangement and can therefore be targeted with the ALK inhibitors crizotinib and ceritinib. While crizotinib is the standard first-line therapy, ceritinib has gained approval for use with patients who are crizotinib-refractory. Ceritinib showed clinical activity in both crizotinib-pretreated and ALK-inhibitor-naïve patients in the single-arm, multicentre, phase II, ASCEND-2 and ASCEND-3 studies [1, 2].

Park et al. presented a combined dataset at the ESMO Asia Congress from both of these studies for the patients with brain metastases at baseline [3]. CNS metastases are a common complication in patients with ALK-positive NSCLC. Seventy-one percent and 40.3 % of the patients had brain lesions at the time of inclusion in ASCEND-2 and ASCEND-3, respectively. Prior radiotherapy to the brain had taken place in 72 % and 54 %, respectively.

At the established dose of 750 mg daily, the median PFS amounted to 6.8 months (ASCEND-2) and 11.0 months (ASCEND-3), by blinded independent central review. The ORRs (as the whole-body response) across these trials were 32.0 % and 60.0 %, respectively. In the patients with active brain lesions selected as the target lesions (e.g., those that progressed following local therapy), the overall intracranial response rates were 39.4 % and 58.8 %, respectively. The intracranial disease control rates exceeded 80 % in both trials.

The safety profile for patients with brain metastases did not differ from that in the overall patient population. This subgroup analysis shows that ceritinib is feasible in patients with brain metastases, as durable intracranial responses can be expected.

REFERENCES

  1. Mok T et al., ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol 33, 2015 (suppl; abstr 8059)
  2. Felip E et al., ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol 33, 2015 (suppl; abstr 8060)
  3. Park K et al., Efficacy and safety of ceritinib in patients with ALK-rearranged non-small cell lung cancer and baseline brain metastases – results from ASCEND-2 and ASCEND-3. ESMO Asia 2015, abstract 419O

More posts

Immunotherapy: management of toxicity

The basis underlying the toxicities of immune checkpoint inhibitors is their promotion of T-cell activity in a physiological manner. “The amplification of the immune system results in autoimmunity,” explained Ross Soo, MD, FRACP, National University Cancer Institute, Singapore.  Common AEs include fatigue, anorexia and arthralgia. Terms that denote immune-related adverse events (irAEs) typically end in -itis or -opathy.

PD-L1 expression is a nightmare in terms of complexity

here are two issues that are tied to the topic of biomarkers in immunotherapies. First, all attempts to define biomarkers have focused primarily on response as a marker of efficacy. We have to be aware, however, that immunotherapies are not targeted therapies, and fast tumor shrinkage is not necessarily observed with this kind of treatment. The efficacy of an immunotherapy is defined by long-lasting tumor stabilization.

Immunotherapy: anti-tumour activity despite extensive pretreatment

The anti-PD-1-antibodies pembrolizumab and nivolumab have been shown to be active in lung cancer. Pembrolizumab is a high-affinity, humanised, monoclonal IgG4κ antibody against PD-1 that prevents the interaction of the receptor with PD-L1 and PD-L2. The KEYNOTE-001 trial demonstrated significant anti-tumour activity of pembrolizumab in advanced NSCLC, with improved outcomes in terms of PD-L1 Tumor Proportion Scores (TPS) ≥ 50 %.

Risks and chances in patients with oligometastatic disease

Against the background of improved systemic therapies, there are rising expectations with regard to the potential cure of NSCLC patients who have a limited number of haematogeneous metastases. “Most studies define oligometastasis as one to three, or one to five lesions,” explained Suresh Senan, MRCP, FRCR, PhD, VU University Medical Centre, Amsterdam, The Netherlands.

Disease progression on EGFR TKI therapy: what to do after erlotinib, gefitinib and afatinib?

The most common mechanism of acquired resistance is the T790M mutation within exon 20 of the EGFR gene (Figure 1). Indolent slow tumour growth typically occurs when this mutation emerges. “Repeated imaging may be necessary to identify progression,” explained Pasi A. Jänne, MD, PhD, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, USA, during a symposium at the ESMO Asia Congress.

EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options

Non–small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations represents a defined molecular subset of lung cancer that can be targeted with EGFR tyrosine kinase inhibitor (TKI) therapies. Erlotinib, gefitinib and afatinib have been approved as first-line treatment options for EGFR-mutation-positive NSCLC.